Type I interferon (IFN) is shown to control the reversible quiescence of a primitive human bone marrow mesenchymal stem cell (MSC) subpopulation. A 24 h pre-treatment of Stro1 þ / GlycoA-or CD45-/GlycoA-subpopulations with a monoclonal antibody (mAb) against the IFNAR1 chain of the human type I IFN receptor (64G12), or with a polyclonal anti-IFNa antibody, resulted in a marked increase in the number of very large colonies (CFU-F 43000 cells) obtained in the presence of low, but necessary, concentrations of bFGF. Over a 2-month culture period, this short activation promoted a faster and greater amplification of mesenchymal progenitors for adipocytes and osteoblasts. Activation correlated with inhibition of STAT1 and STAT2 phosphorylation and of STAT1 nuclear translocation. A non-neutralizing anti-IFNAR1 mAb was ineffective. We demonstrate that control and activated MSCs express ST3GAL3, a sialyltransferase necessary to produce the embryonic antigens SSEA-3 and -4. Interestingly, activated MSC progeny expressed SSEA-3 and -4 at a higher level than control cultures, but this was not correlated with a significant expression of other embryonic markers. As MSCs represent an essential tool in tissue regeneration, the use of 64G12, which rapidly recruits a higher number of primitive cells, might increase amplification safety for cell therapy.
Introduction
Unlike pluripotent human embryonic stem cells (hESCs), which spontaneously sustain large-scale expansion, adult somatic stem cells consist of rare sub-populations of quiescent or slow cycling cells with a limited capacity for self-renewal in vitro, together with a loss of telomerase activity. Mesenchymal stem cells (MSCs) were initially isolated by Friedenstein et al. 1 They consist of a heterogenous and still incompletely characterized cell population. [2] [3] [4] [5] [6] [7] They can be found in tissues of various origins such as bone marrow, adipose tissue, synovial membrane, placenta, umbilical cord and also in cord blood. 4, [8] [9] [10] [11] They are of great interest for use in tissue engineering and cell therapy. 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] (Lazarus et al., Blood, 2000, 96: 392a, abstract). These primitive stem cells can differentiate into mature cells of the mesodermal lineage, like osteoblasts, chondroblasts or adipocytes. 3, [21] [22] [23] One group has also obtained differentiation into cells derived from ectoderm, such as neural cells 21 in mouse, or endoderm, such as functional hepatocyte-like cells in human. 24 The multifunctional cytokine transforming growth factor-b1 (TGF-b1) has been shown previously to play an important role in the regulation of the proliferation of stem cells in vitro, such as human hematopoietic stem cell (hHSC) subpopulations, [25] [26] [27] [28] and primitive keratinocytes. 29 Thus, the use of antisense oligonucleotides has revealed that hHSC quiescence is mediated in part through an autocrine loop involving TGFb1. [30] [31] [32] [33] Similar results have been obtained using either antibodies against TGF-b 25, 31, 34 or antibodies against the TGF-b cell-surface type II receptor (anti-TbR-II). 35 The aim of the present study was to address the question of a possible involvement of type I interferons (IFN), as negative regulators of the cell cycle of human bone marrow-derived mesenchymal precursor cells, as IFNa has been described as a potent inhibitor of marrow stromal cells. [36] [37] [38] As a tool to block IFN signalling, we previously produced and characterized a neutralizing monoclonal antibody, 64G12, directed against IFNAR1, one of the two polypeptide chains constituting the receptor for IFNa, b and o. 39, 40 The anti-IFNAR1 antibody, 64G12, has been shown to neutralize all human type I IFNs. 39, 40 In this study, we demonstrate that IFN, at very low concentrations, could control high proliferative potential -Quiescent (HPP-Q) cells. We observed that the gene ST3GAL3, encoding for a SSEA-4 synthase, is well-expressed in MSCs. However, the expression of SSEA-3 and -4 was not correlated with the expression of any other embryonic markers.
Materials and methods

Bone marrow cell isolation
Bone marrow cells were obtained during orthopedic surgery after informed consent of the donors, according to the Helsinki protocol. Mononuclear cells, recovered by Ficoll density gradient centrifugation, were enriched in the specified subpopulation, using the relevant micromagnetic beads from Miltenyi Biotec (Paris, France). The Stro1 þ IgM antibody, obtained from Developmental Studies Hybridoma Bank (DSHB) (University of Iowa, Iowa City, USA) was purified by affinity chromatography and used at the concentration of 1 mg/10 6 cells. The Stro1 þ sub-population was obtained by an indirect method, using rat anti-mouse IgM microbeads. The CD105 þ , CD45 -/GlycoA À and Stro1 þ /GlycoA À sub-populations were isolated, using the corresponding microbeads from Miltenyi, according to the manufacturer's protocol.
Human pluripotent cell lines
hESCs were used as positive control for embryonic markers. The hESC were hES2 cells provided by embryonic stem (ES) cell International (ESI), and cultured according to the supplier's instructions. Briefly, hESCs were amplified in an undifferentiated state on human extracellular matrices replacing murine embryonic fibroblast (MEF) feeders in a culture medium consisting of 80% knockout (KO) Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Fisher Scientific, Illkirch, France), 20% KO Serum Replacement (KO SR, Invitrogen), 1 mM L-glutamine (Invitrogen), 0.1 mM b-mercaptoethanol (Sigma), 1% nonessential amino acids (NEAA), and 4 ng/ml human basic fibroblast growth factor (bFGF) (Preprotech, Paris, France) and conditioned by hMSCs.
Cytokines and extracellular matrix
Transforming growth factor b1 (TGF-b1) was from R&D (UK), basic fibroblast growth factor (bFGF) from Peprotech and used at the specified concentrations. IFNa 2 (Roferon-A, Roche, Hppmann-La-Roche, Grenzach-Wyhlen, Germany) and human plasma fibronectin were from Roche Diagnostics (Roche, Meylan, France).
Antibodies
For cell activation, antibodies were as follows: two anti-type I IFN receptor (anti-IFNAR1) monoclonal antibodies were raised against the recombinant extracellular region of human IFNAR1, one of the two transmembrane glycoproteins constituting the Type 1 IFN receptor, as described in previous studies. 39, 40 The first antibody, 64G12, inhibits the binding of radiolabelled recombinant human IFNa 2, IFNa 8, IFNb and IFNo to their cell surface receptor, and the biological activity of all type I IFN tested. Fab from 64G12 were also prepared. The second anti-IFNAR1, 34F10, binds to the IFN receptor with the same affinity as that of the 64G12 antibody, but does not inhibit either the binding or the biological activity of any type of IFN tested. AntiIFNa was prepared by one of us and was sheep IgG anti-human IFNa. Each antibody was used at the specified concentrations.
For immuno-phenotypic analysis, antibodies were as follows: anti-SSEA-3 and -4 were obtained from the DSHB and used at a dilution of 1/5 and 1/20, respectively; anti-OCT-4, anti-TRA1-60 and anti-TRA1-81 from Santa Cruz and used at the concentration of 1/50. Detection of the unlabelled antibodies was performed with goat anti-rat IgM labelled with Alexa 488 for anti-SSEA-3 and goat anti-mouse IgG labelled with Alexa 633 for anti-SSEA-4. All the Alexa-labelled goat antibodies were from Molecular Probes Europe (Leiden, The Netherlands) and used at the 1/200 dilution (10 mg/ml). Fluorescein isothiocyanate (FITC)-labelled CD105 was from Caltag. Isotypic controls were performed with the corresponding irrelevant immunoglobulins.
For transduction studies, antibodies against phosphorylated and non-phosphorylated STAT1 and 2 from BioLabs were used at the respective dilutions of 1/50 for the phosphorylated and 1/200 for the non-phosphorylated forms. The primary antibody was revealed by an FITC-labelled goat anti-rabbit diluted 1/50.
Long-term cultures
Long-term expansion assays were carried out in 25 cm 2 tissue culture plates. Cultures were initiated with the purified populations plated at the above-specified concentration. After reaching no more than 70-80% confluency, expanded MSC populations were detached by trypsinization (Boehringer, Ingelheim, Germany), counted and replated at the same concentration. Cultures were continually passaged until the growth capacity of the cells was exhausted. Culture medium was completely renewed two times per week. The cumulated total cell outputs were calculated assuming that all the cells from the previous passage had been replated. For each cell population (control and 64G12 activated MSCs), cultures were performed in triplicate. At each step, cell viability was evaluated by Trypan blue exclusion. (Falcon) . Under this condition, cell density was 10 times lower to ensure better counting of colony number versus colony cell size. Volumes of culture medium were modified accordingly. Complete medium (CM) was constituted by MEMa without nucleotides (Invitrogen), supplemented with 10% selected Hyclone serum (Perbio Science, Brebieres, France) and 2 mM glutamine (Invitrogen). Cells were allowed to adhere for 48 h at 371C and 5% CO 2 . Wells were then washed twice and the remaining adherent cells were further cultured for 24 h in CM with or without 64G12 at 50 mg/ml. Medium was than replaced by CM with bFGF at the final concentration of 0.3 ng/ml. Cells were cultured for 14 days with media renewal twice a week (containing 0.3 ng/ml bFGF but no 64G12). Cells were then fixed, and stained with Giemsa and colonies were photographed. Colony size was evaluated by counting cells on enlarged photographs. Colonies with less than 50 cells were not counted. Small colonies were classified into colonies from 50 to 100 and 100-1000 cells. Large colonies were classified into colonies from 1000 to 3000 and more than 3000 cells.
CFU-F cultures
Differentiation culture protocols
MSCs were treated to test their differentiation potential. For adipogenic differentiation, cells were cultured up to confluency and fed in low-glucose DMEM (Invitrogen) with 20% fetal calf serum (FCS), 0.5 mM IBMX (Sigma), 60 mM indomethacin (Sigma) and 10 À6 M dexamethasone (Sigma) with medium renewal every other day for 3 weeks. Usually, the first adipocytes appeared at the end of the first week. Adipocytes were stained by Oil Red O.
For osteogenic differentiation, after confluency, MSCs were maintained in low-glucose DMEM, 10% FCS, 2 mM 2 bglycerophosphate, 0.15 mM ascorbate-2-phosphate and 10 À7 M dexamethasone. Osteoblasts were revealed by alkaline Phosphatase, using the Sigma-Aldrich kit and following the manufacturer's procedure.
Immuno-phenotypic quantification by laser scanning cytometer
After trypsinization, MSCs at the specified passage were plated on Teflon-covered immunofluorescence slides coated with human fibronectin (1 mg/cm
2 ) at the cell density of 2500 cells/cm 2 and grown for 2-3 additional days. Samples were then processed for antigen expression. Cells were fixed for 5 min by methanol at À201C, washed twice with phosphatebuffered saline (PBS) and once with PBSFbovine serum albumin (BSA) 0.5%. The specific antibodies were applied at the above-specified concentrations for 30 min at 41C. After three washes with PBS-BSA 0.5%, when unlabelled primary antibodies were used, incubation with the relevant labelled secondary antibody was performed for 30 min at 41C. For nuclear staining, 7-amino actinomycin D (7-AAD) (Sigma) at the concentration of 5 mg/ml in PBS was applied to slides for 5 min. After three washes with PBS, preparations were mounted in 75% glycerol in PBS. Appropriate negative controls were used to determine background signal. Analysis was performed using a laser scanning cytometer (LSC) (CompuCyte Corp, Cambridge, MA, USA), which provided the percentage of positive cells as well as the median value of fluorescence (arbitrary units, a.u.). Acquisitions and data analyses were performed using Wincyte software (CompuCyte Corp).
Detection of apoptosis
A total of 64G12 activated and control MSCs were harvested after 14 days of culture and treated with the Annexin V-FITC Kit (Beckman-Coulter, France) following the manufacturer's instructions. The percentage of apoptotic cells was determined by flow cytometry analysis using a FACS Vantage (Becton Dickinson).
Cell lysis and immunoblotting of phosphorylated STATs proteins
MSCs were cultured in four flasks at 300 cells/cm 2 in CM medium containing 10% FCS. When cells reached half confluency, flasks were washed with PBS and left overnight in CM medium containing 2% FCS, then in FCS-depleted medium for 2 h. Four different conditions were tested: (1) 30 min in FCSdepleted medium alone; (2) 15 min with 2000 U IFNa; (3) 30 min with 64G12 followed by 15 min with 2000 U IFNa; and (4) 30 min with 64G12. Cells were then washed, trypsinized and counted. They were then centrifuged and resuspended in a small volume. The cell pellet (around 10 6 cells) was washed with PBS and lysed in 1% Triton X-100 (20 ml), 50 mM Tris, pH 8, 150 mM sodium chloride, 10% glycerol, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 1 mM magnesium chloride, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride , aprotinin, leupeptin and pepstatin (5 mg/ml each). After 20 min shaking at 41C and a 10 min centrifugation at 14000 r.p.m., the supernatant was collected. Twenty microlitres of 2 Â sodium dodecyl sulfate (SDS) buffer were added to the supernatant, heated for 10 min at 901C and 30 mg of proteins was fractionated by 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) under reducing conditions, transferred to polyvinylidene difluoride filters (PVDF; Boehringer Mannheim) and probed with the appropriate primary specific antibodies for 1 h at 201C, followed by the addition for 45 min of secondary antibody horseradish peroxidase (HRP-conjugated goat anti-mouse or anti-rabbit (Jackson ImmunoResearch Baltimore, USA), 1/60000). PVDF blots were developed using the SuperSignal WestPico kit (Pierce, Rockford, USA).
Semi-quantitative RT-PCR
Total DNA-free RNA was prepared from Trizol lysed cells as described by the manufacturer (Invitrogen). Complementary DNA (cDNA) was prepared using Superscript RNAse H À reverse transcriptase (RT) and poly-T primers (both Invitrogen). For RTpolymerase chain reaction (PCR), the equivalent of 0.5 mg RNA was amplified using Taq polymerase (Invitrogen) and the primers as follows: ST3GAL3: ST3 b-galactoside,a-2,3-sialyltransferase 3, sense primer: TTGGCCTGCCCTTCAACAAT, antisense primer: GTGGTGCCTGGGCCTCTATG GenBank accession: BC050380; POU5F1: transcription factor 1 (OCT-4), sense primer: CTCCTGGAGGGCCAGGAATC, antisense primer: CCACATCGGCCTGTTATAT (GenBank accession no: Z11898); GAPDH: glyceraldehyde-3-phosphate dehydrogenase, sense primer: GAAGGTGAAGGTCGGAGTC, antisense primer: GAAGATGGTGATGGGATTTC (GenBank accession no: NM_002046.) Products were amplified for 35 cycles of 941C (30 s), 601C (45 s) and 721C (30 s) using a PTC100 thermocycler (Bio-Rad Lab, Marnes La Coquette, France), and products were visualized on a 1.5% agarose gel with ethidium bromide.
Real-time quantitative PCR using TaqMan low-density arrays
MSCs at passage 3 and 5, and HESCs were harvested using Qiagen reagent following the manufacturer's protocol. Total RNA was prepared according to standard protocols and 5 mg of RNA was treated by Dnase (Ambion, Applied Biosystems, Courtaboeuf, France) to avoid genomic DNA contamination in subsequent RT-PCR. RNAs were reverse-transcribed using the high capacity cDNA Archive kit (ABI Prism, Applied Biosystems, Courtaboeuf, France). Each TaqMan Low Density Array was designed for quantification of human genes. The assays were chosen among the TaqMan Gene Expression Assay library to be representative of hESC self-renewal (NANOG: Hs02387400_g1, SALL4: Hs00360675_m1, LIN28: Hs00702808_s1, TERT: Hs00162 669_m1, POU5F1: Hs00742896_s1, ZFP42: Hs00399279_m1, UTF1: Hs00747497_g1, TDGF1: Hs02339499_g1). Gene expression was normalized to endogenous housekeeping gene 18S rRNA and hES2 as sample calibrator. An equal amount of input cDNA (600 ng) was used per reaction and all PCR were performed in duplicate. Results were analyzed using ABI PRISM 7900HT Sequence Detection System (ABI), and changes in gene expression levels were calculated using the 2 ÀDDCT method.
Statistical analysis
The Student's t-test was used to determine the statistical significance of differences between means of several (n) experiments.
Results
Effect of 64G12 anti-IFNAR1 blocking antibody on Stro1 þ /GlycoA-longÀterm culture Figure 1a compares amplification curves of MSCs with 0.3 ng/ml bFGF, with or without 50 mg/ml 64G12 antibody added for 24 h only at the onset of the long-term cultures. 64G12 neutralizes the activity of all human type I IFNs 39 by blocking IFNAR1, one of the two polypeptide chains of the human type I IFN receptor. We can observe that the short activation of primitive MSCs by a 24 h pre-treatment by anti-IFN is sufficient to trigger immediately an exponential growth, contrasting with the 25 days of slower growth observed at the beginning of the untreated control culture. Moreover, the 64G12-treated cells expanded up to a 10 9 cell output (30 doublings) within 2 months, whereas control cells expanded only up to a 10 7 cell output (24 doublings).
Activated cells from passage 10 retained their potentialities to differentiate towards adipocytic (Figure 1b) and osteogenic ( Figure 1c) lineages, when cultivated in the appropriate media. 37 Sequential effect of anti-IFN and low concentration of bFGF on CFU-F In Figure 2a , a histogram of colony frequency versus colony cell size indicates clearly that in short term cultures with 0.3 ng/ml bFGF, a 24 h pre-treatment with 50 mg/ml 64G12 antibody, at the onset of the culture, was necessary to trigger the appearance of very large colonies with more than 3000 cells. Colonies with less than 50 cells were not considered. Figure 2B -a views an example of a very small colony with around 100 cells; Figure  2B -b views a colony with less than 1000 cells, still considered as a small colony. Very small and small colonies are composed of large cells with a low nucleocytoplasmic (N/C) ratio. Colonies with more than 1000 cells were considered as large colonies in routine experiments. Large colonies had small cells with a N/C ratio five times greater than cells from small colonies and they grew faster as suggested by the two first passages shown in Figure 1a . In more precise experiments with cells plated at lower cell density, colonies were further classified into large colonies with less than 3000 cells and very large colonies with more than 3000 cells (Figure 2B-c) . The larger colonies could reach a doubling time around 24 h. The total colony number in the activated culture was increased, an observation, which favors the hypothesis that large colonies are not derived from preexisting small colonies, but rather from quiescent high proliferative potential, HPP-Q cells, activated by the anti-IFNAR1 antibody 64G12.
The antibody 64G12 is necessary but not sufficient to amplify quiescent high proliferative potential HPP-Q MSCs as detailed in Figure 2c . Under conditions without additive, with antibodies but without bFGF or with bFGF alone at 0.3 ng/ml, no large colonies appeared. Very large colonies with more than 3000 cells appeared only when bFGF was added after a 64G12 or anti-IFNa pre-treatment. A similar large colony number was obtained with Fab 64G12 and bFGF, excluding a non-specific effect of 64G12 Fc fragments. 34F10 antibody recognizes IFNAR1 but does not neutralize the transduction pathway. When the 34F10 antibody alone was added, results were similar to those obtained with 64G12 added alone. In contrast, bFGF with 34F10 was ineffective on large and very large colony formation. When a large, non-physiological concentration of 50 ng/ml bFGF was added, large colonies with 1000-3000 cells was observed much later than large colonies in 64G12-activated cultures: the population doubling . With large nonphysiological concentrations of bFGF alone (50 ng/ml), no colonies with more than 3000 cells were observed and colonies with 1000-3000 appeared much more slowly (*) than large and very large colonies obtained with 64G12 or anti-IFN and 0.3 ng/ml bFGF.
time was over 72 h and no colony with more than 3000 cells was detected. IFN has been also described as an inducer of apoptosis. 41 Consequently, we tested whether the appearance of large colonies could be due to 64G12 neutralizing the apoptotic effect of IFN. Cells after contact with 64G12 were analyzed by Annexin-V staining and flow cytometry. There was no difference in the number of apoptotic cells in the activated versus the control culture: 2.0670.8% for activated MSCs versus 2.3670.9% for control (n ¼ 3). Therefore, as 64G12, or antiINFa, activate the quiescent cells even if added for a very short time before bFGF addition, the large colonies did not result from an increase in size in response to a continuous stimulation of cell proliferation by 64G12, or from a protective effect of 64G12 against apoptosis.
64G12 antibody activates MSCs by STAT phosphorylation inhibition
The effect of 64G12 on MSCs was studied at the molecular level. As IFN transduction is mediated by the STAT pathway, 42, 43 expression of STAT1 and STAT2 (constitutively expressed) and their phosphorylated counterparts was evaluated by immunoblotting and immunofluorescence on MSCs with and without 64G12. Immunoblotting results are shown in Figure 3a . Phosphorylated STAT1 and STAT2 were both detectable in MSCs after contact with IFNa for 30 min. In contrast, in control MSCs as well as those preincubated with 64G12 alone or 64G12 with IFNa, phosphorylation of STAT1 and 2 was not observed. The same blots showing the P-STATs were disrupted and reblotted with anti-STAT1 or anti-STAT2 (A, lower panel) to confirm that equal amounts of protein were loaded. Figure 3b shows that, in the presence of IFNa, 64G12 blocked the translocation of STAT1 from the cytoplasm to the nucleus (3B-b), whereas in cells without added 64G12, STAT1 was translocated into the nucleus in response to IFNa (3B-a). Therefore, by blocking the phosphorylation of STAT1, which constitutes the first step of transduction activation, 64G12 prevented STAT1 translocation.
Expression of human embryonic markers by the progeny of control and 64G12-activated Stro1 þ /GlycoAmesenchymal cells
As OCT-4 has been previously described as slightly expressed in primitive MSCs, 44 we searched for the expression of genes representative of human embryonic stem cells (hESC) in MSC subpopulations activated or not by 64G12.
Comparative transcriptomic studies of control and activated MSC progeny from three different bone marrow cultures by quantitative real-time PCR are shown in Figure 4a . All the genes studied, such as TERT, POU5F1 (OCT-4), ZFP42 (REX1), TDGF1 (CRIPTO), SALL4, LIN28, UTF1 and NANOG, were completely extinguished as compared to their expression in hESC, chosen as a sample calibrator with a value of 1. By semiquantitative RT-PCR also, POU5F1 was not significantly expressed. However, we observed that ST3GAL3, the gene encoding for a-2,3-sialyltransferase, an SSEA-4 synthase, was well expressed both in control and activated MSC cultures (Figure 4b ). Consequently, we looked for the expression of SSEA-3 and -4 antigens in control and activated MSC cultures. Indeed, these two antigens, together with 0CT-4, TRA1-60 and TRA1-81, are classical markers of human embryonic stem cells (hESC).
SSEA-3 immunofluorescence of control and activated cultures after 14 days are shown in Figure 5a and b by LSC quantification of positive cells and mean fluorescence in arbitrary unit (a.u.). SSEA-3 expression was significantly increased on 64G12-treated cell progeny: 48% of activated cells were positive, with a mean fluorescence of 5.4 Â 10 6 a.u., versus 14% positive cells in the control culture with a mean fluorescence of 1.8 Â 10 6 a.u. When colonies were individually analyzed, SSEA-3 and -4 were always more expressed on large colonies from activated MSCs than on controls (data not shown).
After seven passages, 73% of stimulated MSCs were positive for SSEA-3 with a mean fluorescence of 7.0 Â 10 6 a.u (Figure 5d ) when the control culture increased to 30% of positive cells with a mean fluorescence of 3.7 Â 10 6 a.u. (Figure 5c ). SSEA-4 was also higher on stimulated cells, with 86% of positive cells with a mean fluorescence of 1.7 Â 10 6 a.u. (Figure 5f ), versus 43.7% positive cells with a mean fluorescence of 0.8x10 6 a.u. for the control culture (Figure 5e ).
OCT-4, TRA 1-60 and TRA 1-81 studied by immunofluorescence were not detected (data not shown).
Effects of 64G12 on different MSC subpopulations
The above results were obtained on the Stro1 þ /GlycoAsubpopulation. Since the precise phenotype of CFU-F is unclear at present, three other mesenchymal subpopulations, Stro1 þ , CD105 þ and CD45/GlycoA-, were isolated and treated with 64G12. Results are shown on Table 1 . A significant increase in the number of large colonies after treatment with 64G12 was also obtained with these subpopulations. This implies that all these subpopulations contained quiescent primitive cells under the control of IFNa. However, it is interesting to note that the CD45-/GlycoA-subpopulation required a plating density six times lower than the others to provide a similar number of large colonies.
Discussion
In this study, we have demonstrated that a quiescent primitive sub-population of human MSCs is under the reversible growthinhibitory control of the IFNa/b. When an MSC-enriched subpopulation of cells from bone marrow were cultured in the presence of a neutralizing antibody (64G12) directed against IFNAR1 (one of the two polypeptide chains constituting the receptor for IFNa, b and o 39, 40 ), a significant number of additional very large colonies appeared that were very seldom or not observed in control cultures. Similar results were obtained with blocking antibody directed against IFNa. A 24 h pretreatment with anti-IFN of primary cells isolated from the bone marrow, before initiation of in vitro culture, was sufficient to activate the highly proliferative progenitors. In long-term Interferon controls human stem cell proliferation A Hatzfeld et al follow-up culture, pre-treated cells were able to generate over 2 months an output of cells at least a 100 times greater (10 9 cell range) than in control culture conditions. Moreover, it appeared that the pre-treated cells were able to enter into an exponential proliferative expansion without the lag phase typically observed in control cultures. This further supports the presence of subpopulations of quiescent or slowly cycling progenitor cells that can be activated. Importantly, progenies of quiescent cells generated after blocking IFN maintained their potential to differentiate towards adipocytes and osteoblasts, even when expanded up to the 10th passage.
It was striking that extremely low concentrations of IFNa in the range of 0.4-4 IU/ml, which corresponds to 4-40 pg/ml, was sufficient to inhibit 70-80% of the large colony formation (data not shown). This is very similar to our previous studies of TGF-b in early hematopoietic progenitor cells. Primitive HPP-Q cells 
Table 1
Comparison of the large colonies obtained with four different subpopulations of MSCs activated or not by 64G12 antibody
Subpopulations
64G12
Number of large colonies Interferon controls human stem cell proliferation A Hatzfeld et al were sensitive to growth inhibition by a TGF-b concentration as low as 10 pg/ml. 45 For TGF-b, this corresponds to the physiological concentration present in plasma (10-300 pg/ml). Although IFN is not usually detectable in normal plasma, human peripheral blood mononuclear cells have been shown to express low levels of IFN mRNA, 46 suggesting that a paracrine or an autocrine secretion of IFNa may also participate in this homeostatic regulation.
Human stem and progenitor cell control by the TGF-b superfamily has been extensively studied in vitro with various cell types such as hHSCs, [25] [26] [27] [28] keratinocytes, 29 and more recently, human adult embryonic stem cells (hESCs). [47] [48] [49] [50] [51] [52] [53] Our preliminary study of the effect of TGF-b on MSCs (data not shown) also indicates that blocking TGF-b can activate a subpopulation of highly proliferative progenitor cells. Interestingly, however, the simultaneous addition of neutralizing antibodies for TGF-b and IFN had no additive effect, suggesting that both treatments activated similar cell subpopulations. Such a possibility was also suggested by the study of Giron-Michel et al. 54 Using 64G12 in vitro to activate a sub-population of human primitive hematopoietic progenitors, they suggested that low concentrations of endogenous IFN could have an effect similar to endogenous TGF-b to activate HPP-Q HSCs. 33 Altogether, these observations on hHSCs and hMSCs suggest that IFN and TGF-b might be targeting the same pathway responsible for maintaining certain subpopulations of progenitor cells in quiescence.
It has been shown that type I IFNs inhibit cell proliferation by inducing G1 cell cycle arrest. Thus, inhibition of the action of endogenously produced type I IFNs by blocking antibody or antibody against the receptor could release cells from G1 cell cycle arrest and thereby promote response to mitogens such as bFGF. This may explain why a short exposure of MSCs to 64G12 of no more than 24 h, before culture with bFGF at very low concentrations, is sufficient to activate sustained proliferation of the quiescent highly proliferative progenitor cells. 64G12 may be acting as a 'competence growth factor', with bFGF acting as a 'progression growth factor' in a model system as suggested by Pledger et al. 55 and Stiles et al. 56 We have similarly demonstrated that the addition of anti-TGF-b antibody to hematopoietic progenitor cells induced the quiescent cells first to express cytokine receptors, 31, 34 then to respond very efficiently to various cytokines such as SF, IL6, FL and TPO added at low concentrations.
A somewhat surprising finding was the expression in MSCs of the stage-specific embryonic antigens 3 and 4 (SSEA-3, SSEA-4), which are commonly used with other markers such as OCT-4, TRA1-60 and TRA1-81 to characterize the non-differentiated state of hESCs. This was in agreement with our finding of ST3GAL3 gene expression in MSCs at a similar level as in human embryonic stem cells. Even more interesting was the increased expression of SSEA-3 and -4 in cultures from 64G12-treated cells. This is in agreement with a recent study examining SSEA-4 in MSCs from human bone marrow. 57 Very surprisingly, these authors showed that with increased passages of MSCS, there was a significant increase in SSEA-4-positive cells up to as high as 80%, despite the fact that continuing passages of MSCS led to senescence of these cells. Using quantitative PCR, we could not demonstrate any significant expression of typical markers of hESCs (TERT, POU5F1, ZFP42, TDGF1, SALL4, LIN28, UTF1 or NANOG) in control or 64G12-treated cells. Therefore, the SSEA-3 and -4 antigens may not necessarily be associated always with the embryonic state. This is supported by the conclusion from a recent study demonstrating that SSEA-3 and SSEA-4 are not essential for hESC pluripotency. 58 The frequency of the highly proliferative mesenchymal progenitor cells in bone marrow appears to be very low. Reyes et al. 23 indicated that 0.02-0.08% of CD45À/GlycoAÀ cells resulted in clusters of mesodermal progenitor cells (MSCs). This percentage is similar to the number of MSCs producing large colonies we observed after 64G12 activation of the CD45À/ GlycoAÀ subpopulation (0.07%). Moreover, this selected subpopulation allows for at least a sixfold greater enrichment compared with Stro1 þ , Stro1 þ /GlycoAÀ and CD105 þ subpopulations. Comparison of long-term growth curve of SSEA-4 þ MSCs according to Gang et al. does not indicate any improvement over our long-term culture method, even though they use richer growth conditions. Comparison of various MSC selection methods with the selection of SSEA-4 þ MSCs has still to be performed to determine which method provides the best recovery of HPP-Q MSCs with the largest expansion in short-term culture and the best maintenance in long-term culture.
One important application of human primitive MSCs is their use for tissue repair. Clinically, MSCs have been used with promising results in various disorders that depend on their capacity for differentiating into mesenchymal cells such as cartilage and bone. These cells have proved their efficiency in treatment of Osteogenesis Imperfecta, 16, 17 metachromatic leukodystrophy and Hurler syndrome. 18 Another important application of MSCs is derived from their apparent immuno-suppressive effect. Co-transplant of MSCs enhanced bone marrow engraftment and minimized periods of aplasia. Autologous MSC transplantation improved the rate of platelet reconstitution of patients, when compared with the control group, suggesting a faster engraftment. 19 In allogenic transplantation, infusion of MSCs resulted in a strikingly low incidence of graft-versus-host disease. 14, 20 (Lazarus et al., Blood, 2000, 96: 392a, abstract) Interestingly, the 64G12 antibody, administered together with a sub-effective dose of cyclosporine, has been shown to induce prolonged survival of skin allografts in major histocompatibility complex divergent cynomolgus monkeys. 15 In view of their tissue differentiation and immunoregulatory potential, MSCs represent important cells in regenerative medicine. One of the major limitations has been the slow growth of MSCs and their senescence upon passaging and expansion. The stress of prolonged expansion also increased the possibility of selection of spontaneously transformed clones during expansion. 59 The use of 64G12, which rapidly recruits a higher number of highly proliferative progenitor cells as shown in this study, is to the best of our knowledge, the fastest reported technique for safely augmenting MSC expansion for clinical applications.
